Cencora Inc. (COR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, COR scores 70 out of 100, a letter grade of B-, with the verdict label "Roarable Buy — Sound Institutional Accumulation." The fundamental cash engine pillar scores 19 of 20, citing ROIC of 26.8% and FCF yield of 5.08%, making it the strongest pillar and the main upside driver in the rating. Whale 13F flow scores 13 of 20 for institutional accumulation and options positioning, suggesting institutional interest is present but not dominant. Insider conviction scores 14 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 11 of 20, reflecting a beta of 0.88 and sector sensitivity, the weakest pillar and a signal that the stock's market-relative behavior is only moderately favorable. Forensic balance sheet scores 13 of 20, citing Altman Z of 5.27, Piotroski F of 6/9, and Debt/Equity of 3.97; the Z-score is strong while the leverage ratio warrants attention. For a prospective investor, the key tradeoff is a high-quality cash-return profile against a valuation that the market data shows at 40.6x trailing earnings and 21.6x EV/EBITDA, alongside thin reported margins. This is analytical context, not personalized financial advice.

Cencora Inc. is a NYSE-listed issuer in the Health Care sector and Other Pharmaceuticals industry, per the SEC profile. Beyond its sector and industry classification, the source data does not describe its specific products, customers, or revenue model. The reported revenue of $321332.8M for FY 2025 indicates a very large operating scale, but the source data does not explain how that revenue is generated.

Per the SEC financials, revenue grew from $262173.4M in FY 2023 to $321332.8M in FY 2025, while net income moved from $1745.3M to $1554.2M over the same span. Market data shows gross margin of 3.6%, operating margin of 0.8%, and net margin of 0.5%, and ROIC of 26.8%. The forensic section reports an Altman Z-Score of 5.27 and a Piotroski F-Score of 6/9. Debt/Equity of 3.97 and reported debt rising to $7579.5M in FY 2025 from $5935.3M in FY 2024 point to a leveraged balance sheet, while the FY 2023 debt figure of $73618.3M appears in the source without further explanation.

The news wire contains six items, all tagged to COR with a YELLOW light and MARKET WIRE impact label, from Yahoo Finance, Seeking Alpha, Benzinga, TradingView, and Simply Wall St. Headlines include "Cencora (COR): 3 Reasons We Love This Stock," "AI Disruption May Benefit Cencora More Than Hims & Hers (NYSE:COR)," "Cencora (COR) Stock Still Looks Undervalued After Its 173% Run," "Cencora Gears Up to Report Q4 Results: How to Play the Stock?," and "Cencora (COR) Has Investors Asking A Bigger Question." The summaries are generic market-action descriptions and do not state specific catalyst details. Potential watch items implied by headlines include an upcoming Q4 results report and a reference to a prior 173% run, though the source does not quantify either. The Butterfly Supply-Chain Graph reports no supply-chain relationships and no proprietary signals.

• What drove the revenue expansion and how durable is the reported gross margin of 3.6% given the margin profile?
• What explains the FY 2023 free cash flow deficit of $-7886.5M and the $73618.3M debt figure, and how did the balance sheet move to its current position?
• Why is EPS unreported for all three periods, and how does the 8.14 TTM EPS reconcile with reported net income?
• What specific catalysts are expected around the upcoming Q4 results, and what do they imply for the 37.8x forward multiple?
• What institutional holdings and insider transactions support the whale and insider pillar scores, given the holders section is empty?